Table 1.
Clinical and demographic characteristics of IBD patients with a confirmed diagnosis of IIDD.
| CD N = 9 | UC N = 6 | P value | Total N = 15 | |
|---|---|---|---|---|
| Demographic Characteristics | ||||
| Median age at IBD diagnosis, years (range) | 28.32 (11-48) | 32.17 (13-49) | 0.41 | 30.25 (11-49) |
| Female, n (%) | 8 (89%) | 4 (67%) | 0.53 | 12 (80%) |
| Previous personal history of autoimmune diseases, n (%) | 1 (11%) | 1 (17%) | 1.00 | 2 (13%) |
| Family history of IBD, n (%) | 3 (33%) | 0 | 0.23 | 3 (20%) |
| Family history of demyelinating diseases, n (%) | 1 (11%) | 1 (17%) | 1.00 | 2 (13%) |
| Smoking at diagnosis, n (%) | 3 (33%) | 0 | 0.23 | 3 (20%) |
| Ulcerative Colitis: Disease location, n (%) | ||||
| E1, proctitis | 1 (17%) | |||
| E2, left sided colitis | 1 (17%) | |||
| E3, extensive colitis | 4 (67%) | |||
| Crohn’s Disease: Disease location, n (%) | ||||
| L1, terminal ileal | 1 (11%) | |||
| L2, colon | 3 (33%) | |||
| L3, ileocolonic | 5 (56%) | |||
| Crohn’s Disease: Disease behavior, n (%) | ||||
| B1, inflammatory | 8 (89%) | |||
| B3p, perianal penetrating | 1 (11%) | |||
| Disease activity at diagnosis, n (%) | ||||
| Mild | 1 (11%) | 2 (33%) | 0.53 | 3 (20%) |
| Moderate | 6 (67%) | 4 (67%) | 1.00 | 10 (67%) |
| Severe | 2 (22%) | 0 | 0.49 | 2 (13%) |
| Extraintestinal manifestations, n (%) | ||||
| Skin | 2 (22%) | 0 | 0.49 | 2 (13%) |
| Oral | 2 (22%) | 0 | 0.49 | 2 (13%) |
| Anti-TNF alpha therapy, n (%) | ||||
| Infliximab | 3 (33%) | 1 (17%) | 0.60 | 4 (27%) |
| Adalimumab | 2 (22%) | 0 | 0.49 | 2 (13%) |
| Concomitant therapy, n (%) | ||||
| Azathioprine/6-mercaptopurine | 0 | 1(17%) | 0.40 | 1 (7%) |
| Corticosteroids | 1 (11%) | 0 | 1.00 | 1 (7%) |
| Antibiotics | 1 (11%) | 0 | 1.00 | 1 (7%) |
| Median followup in Gastroenterology, years (range) | 10.85 (5-32) | 7.35 (5-39) | 0.41 | 10.5 (5-39) |
Inflammatory bowel disease (IBD), Crohn’s disease (CD), Ulcerative colitis (UC)